The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 69 results
May 2026
-
Media Release
Novartis Canada Recognizes MS Awareness Month with the Third Annual My Krew Campaign
Approximately 90,000 Canadians live with multiple sclerosis (MS), a disease that impacts the central nervous system.1 Canada has one of the highest rates of MS in the world, with an average of 12… -
Media Release
Novartis receives Health Canada approval for ᴾͬ Fabhalta® oral treatment for adults with C3G
Fabhalta® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria.1Phase III APPEAR-C3G…
December 2025
-
Media Release
Scemblix® Receives Positive Funding Recommendations from INESSS for Newly Diagnosed and Previously Treated Adult Patients with Chronic Myeloid Leukemia
Novartis Canada applauds the positive funding recommendations for Scemblix® (asciminib) for both newly diagnosed and previously treated patients with Philadelphia chromosome-positive chronic myeloid… -
Media Release
Scemblix® Receives Priority Access in Ontario Under New FAST Program
Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix® for patients living with cancer.Scemblix® (asciminib) was… -
Media Release
High-risk Early Breast Cancer Patients in Quebec Left Behind by Recent INESSS Recommendation
Quebec has the highest rate of breast cancer in Canada.1 The Government of Quebec recently endorsed lowering the breast cancer screening age for women,2,3 reflecting the province’s commitment…
November 2025
-
Media Release
Novartis Canada Unveils 2025 Health Equity Initiative Winners, Awarding Over $560,000 at Montreal Ceremony with Federal Health Minister, the Honourable Marjorie Michel, in Attendance
The Novartis Health Equity Initiative continues to support projects tackling systemic health disparities and promoting equitable access to healthcare across Canada.To date, the initiative drew over… -
Media Release
Novartis Canada Welcomes Dimitri Gitas as New Country President
MONTREAL, QC, November 25, 2025 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri Gitas as Country…
July 2025
-
Media Release
Health Canada expands approval of Scemblix®, making it an option for newly diagnosed and previously treated chronic myeloid leukemia (CML) patients
• Scemblix® is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies.1,2• … -
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
• Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)• …